1. Letter to the editor regarding "Stabilization of leukocytes from cerebrospinal fluid for central immunophenotypic evaluation in multicenter clinical trials".
- Author
-
Schulte-Mecklenbeck A, Zinnhardt B, Müller-Miny L, Haessner S, Meyer Zu Hörste G, Wiendl H, and Gross CC
- Subjects
- Leukocytes, Cerebrospinal Fluid
- Abstract
Competing Interests: Declaration of Competing Interest ASM, LMM, SH, and GMzH have nothing to disclose. BZ is a current employee and shareholder of F. Hoffmann- La Roche Ltd. HW received honoraria for acting as a member of Scientific Advisory Boards for Janssen, Merck, and Novartis as well as speaker honoraria and travel support from Alexion, Amicus Therapeuticus, Biogen, Biologix, Bristol Myers Squibb, Cognomed, F. Hoffmann-La Roche Ltd., Gemeinnützige Hertie-Stiftung, Medison, Merck, Novartis, Roche Pharma AG, Genzyme, TEVA, and WebMD Global. Heinz Wiendl is acting as a paid consultant for Biogen, Bristol Myers Squibb, EMD Serono, Idorsia, Immunic, Novartis, Roche, Sanofi, the Swiss Multiple Sclerosis Society, and UCB. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgesellschaft (DFG), Deutsche Myasthenie Gesellschaft e.V., Alexion, Amicus Therapeutics Inc., Argenx, Biogen, CSL Behring, F. Hoffmann - La Roche, Genzyme, Merck KgaA, Novartis Pharma, Roche Pharma, and UCB Biopharma. CCG received speaker honoraria from MyLan and DIU Dresden International University GmbH, and travel expenses for attending meetings from Biogen, Euroimmun, MyLan, and Novartis Pharma. Her research is funded by the German Research Foundation (DFG), the German Ministry for Education and Research (BMBF), the European Union (Horizon2020), the IZKF Münster, Biogen, Roche, and Novartis.
- Published
- 2023
- Full Text
- View/download PDF